0001193125-22-254512.txt : 20220930 0001193125-22-254512.hdr.sgml : 20220930 20220929194900 ACCESSION NUMBER: 0001193125-22-254512 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20220930 DATE AS OF CHANGE: 20220929 GROUP MEMBERS: BIOTECH GROWTH N.V. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Revolution Medicines, Inc. CENTRAL INDEX KEY: 0001628171 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 472029180 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-91387 FILM NUMBER: 221281839 BUSINESS ADDRESS: STREET 1: 700 SAGINAW DR CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 415-766-3638 MAIL ADDRESS: STREET 1: 700 SAGINAW DR CITY: REDWOOD CITY STATE: CA ZIP: 94063 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] IRS NUMBER: 000000000 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: SCHWERTSTRASSE 6 CITY: SCHAFFHAUSEN STATE: V8 ZIP: 8200 BUSINESS PHONE: 411724 59 59 MAIL ADDRESS: STREET 1: SCHWERTSTRASSE 6 CITY: SCHAFFHAUSEN STATE: V8 ZIP: 8200 SC 13G 1 d290834dsc13g.htm SC 13G SC 13G

 

 

United States

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

 

 

REVOLUTION MEDICINES, INC.

(Name of Issuer)

 

 

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

76155X100

(CUSIP Number)

September 22, 2022

(Date of Event Which Requires Filing This Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed “ for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

1

CUSIP No.     76155X100

 

  1.    

  Names of Reporting Persons

 

  BB Biotech AG

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

 

  (a)  ☒        (b)  ☐

  3.  

  SEC Use Only

 

  4.  

  Citizenship or Place of Organization

 

  Switzerland

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

with:

 

      5.     

  Sole Voting Power

 

  0

     6.   

  Shared Voting Power

 

  4,602,562

     7.   

  Sole Dispositive Power

 

  0

     8.   

  Shared Dispositive Power

 

  4,602,562

  9.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  4,602,562

10.  

  Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

  ☐

11.  

  Percent of Class Represented by amount in Row (9)

 

  5.2%

12.  

  Type of Reporting Person (See Instructions)

 

  HC, CO

 

2 of 7

CUSIP No.     76155X100

 

  1.    

  Names of Reporting Persons

 

  Biotech Growth N.V.

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

 

  (a)  ☒        (b)  ☐

  3.  

  SEC Use Only

 

  4.  

  Citizenship or Place of Organization

 

  Curaçao

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

with:

 

      5.     

  Sole Voting Power

 

  0

     6.   

  Shared Voting Power

 

  4,602,562

     7.   

  Sole Dispositive Power

 

  0

     8.   

  Shared Dispositive Power

 

  4,602,562

  9.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  4,602,562

10.  

  Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

  ☐

11.  

  Percent of Class Represented by amount in Row (9)

 

  5.2%

12.  

  Type of Reporting Person (See Instructions)

 

  CO

 

3 of 7

Item 1

1(a) Name of Issuer:         Revolution Medicines, Inc.

1(b) Address of Issuer’s Principal Executive Offices:

700 Saginaw Drive, Redwood City, California 94063, United States of America

 

Item 2

2(a) Name of Person Filing: BB Biotech AG (“BB Biotech”) on behalf of its wholly-owned subsidiary, Biotech Growth N.V. (“Biotech Growth”)

2(b) Address of Principal Business Office or, if none, Residence:

BB Biotech AG: Schwertstrasse 6, CH-8200 Schaffhausen, Switzerland

Biotech Growth N.V.: Ara Hill Top Building, Unit A-5, Pletterijweg Oost 1, Curaçao

2(c) Citizenship:         BB Biotech AG: Switzerland

              Biotech Growth N.V.: Curaçao

2(d) Title of Class of Securities         Common Stock, par value $0.0001 per share

2(e) CUSIP Number         76155X100

 

Item 3

N/A

 

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

  (a)

Amount beneficially owned: 4,602,562

 

  (b)

Percent of class: 5.2%

 

  (c)

Number of shares as to which the person has:

 

  (i)

Sole power to vote or to direct the vote 0

 

  (ii)

Shared power to vote or to direct the vote 4,602,562

 

  (iii)

Sole power to dispose or to direct the disposition of 0

 

  (iv)

Shared power to dispose or to direct the disposition of 4,602,562

 

Item 5.

Ownership of Five Percent or Less of a Class

N/A

 

4 of 7

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

N/A

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

This statement is filed jointly by BB Biotech and Biotech Growth. Biotech Growth is a wholly-owned subsidiary of BB Biotech.

 

Item 8.

Identification and Classification of Members of the Group

N/A

 

Item 9.

Notice of Dissolution of Group

N/A

 

Item 10.

Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

5 of 7

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BB Biotech AG

 

Date: September 29, 2022     By:   /s/ Martin Gubler
      Signatory Authority
    Name:   Martin Gubler
    Title:   Signatory Authority
Date: September 29, 2022     By:   /s/ Ivo Betschart
      Signatory Authority
    Name:   Ivo Betschart
    Title:   Signatory Authority
Biotech Growth N.V.      
Date: September 29, 2022     By:   /s/ Jan Bootsma
      Signatory Authority
    Name:   Jan Bootsma
    Title:   Signatory Authority
Date: September 29, 2022     By:   /s/ Hugo van Neutegem
      Signatory Authority
    Name:   Hugo van Neutegem
    Title:   Signatory Authority

 

6 of 7

EX-99.A 2 d290834dex99a.htm EX-99.A EX-99.A

Exhibit A

Joint Filing Statement

We, the undersigned, hereby express our agreement that the attached Schedule 13G (including all amendments thereto) is filed on behalf of each of the undersigned.

 

     

BB Biotech AG

Date: September 29, 2022

    

By:

  

/s/ Martin Gubler

     

Signatory Authority

   

Name:

  

Martin Gubler

   

Title:

  

Signatory Authority

Date: September 29, 2022

    

By:

  

/s/ Ivo Betschart

     

Signatory Authority

   

Name:

  

Ivo Betschart

   

Title:

  

Signatory Authority

     

Biotech Growth N.V.

Date: September 29, 2022

    

By:

  

/s/ Jan Bootsma

     

Signatory Authority

   

Name:

  

Jan Bootsma

   

Title:

  

Signatory Authority

Date: September 29, 2022

    

By:

  

/s/ Hugo van Neutegem

     

Signatory Authority

   

Name:

  

Hugo van Neutegem

   

Title:

  

Signatory Authority

 

7 of 7